Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Aspira Women's Health Inc. (AWHL) vs bioAffinity Technologies, Inc. (BIAF)

Aspira Women's Health Inc. and bioAffinity Technologies, Inc. are both Diagnostics & Research companies. bioAffinity Technologies, Inc. is the larger, with a market value of $9.0M against $2.4M — 3.7× the size. Aspira Women's Health Inc. grew revenue faster over the last twelve months: −8.00% against −23.2%. Aspira Women's Health Inc. has the higher net margin (−117.1% vs −257.3%) and the higher return on invested capital (0.00% vs −408.7%). Across the 16 metrics below, Aspira Women's Health Inc. leads on 12 and bioAffinity Technologies, Inc. on 4.

Valuation

Metric AWHL BIAF Diagnostics & Research median
P/E n/m n/m 33.95
P/S 1.35 0.47 4.87
P/B n/m 0.73 3.12
Price to free cash flow n/m n/m 34.02
EV/EBITDA n/m n/m 25.20
EV/Sales 1.52 0.15 5.66
Earnings yield (93.85%) (1,380.14%) (1.75%)
Free cash flow yield (41.10%) (418.18%) (0.13%)

Profitability

Metric AWHL BIAF Diagnostics & Research median
Gross margin 58.78% 34.61% 50.89%
Operating margin (80.75%) (209.82%) (8.57%)
Net margin (117.07%) (257.33%) (6.37%)
Free cash flow margin (55.32%) (195.90%) 0.00%
Return on equity 201.29% (1,860.15%) (2.92%)
Return on assets (213.58%) (245.51%) (6.71%)
Return on invested capital 0.00% (408.67%) 0.00%

Growth

Metric AWHL BIAF Diagnostics & Research median
Revenue growth (TTM) (8.00%) (23.18%) 7.69%
EPS growth (last fiscal year) 60.22% 61.55% —
Revenue growth, 5-year CAGR 14.66% — 7.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AWHL BIAF Diagnostics & Research median
Debt to equity (0.27) 0.15 0.11
Current ratio 0.52 1.44 2.02
Net debt to EBITDA 0.00 0.57 0.78

Dividend

Metric AWHL BIAF Diagnostics & Research median
Dividend yield — — 0.70%
Payout ratio 0.00 — 0.00

Size

Metric AWHL BIAF Diagnostics & Research median
Market cap 2.44m 9.00m 2.56b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack